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Proposed mechanisms
In studies of tumor cells in vitro, Palti and colleagues observed two distinct effects, both of which depend on the direction of cell division with respect to the applied field. 2 First, they found that cells in the electric field take longer than usual to divide, as shown in figure 1a . Second, they found that dividing cells sometimes disintegrate just before the division process is complete, as shown in figure  1 , panels b and c. They offer an explanation for each effect.
The researchers suggest that cell division is slowed because the electric field hinders the formation and function of the mitotic spindle, the structure that guides the newly replicated chromosomes as they separate into the two daughter cells. also involve polar molecules and structures, and small oscillating electric forces don't appear to have much of an effect on them. The difference, says Palti, is that when the tubulin dimers assemble into the mitotic spindle, they all line up in the same direction. If that direction happens to be orthogonal to the direction of the electric field, the microtubules are less likely to function normally. The proposed mechanism for the destruction of dividing cells stems from the distribution of the electric field in each cell. The cell membrane, a lipid bilayer, acts as a capacitor with high impedance at the frequencies used, so the electric field doesn't readily penetrate the cell membrane. In a quiescent cell, the electric field inside the cell (shown in figure 2a ) is much smaller than the field outside the cell and is largely uniform. But in the late stages of cell division, a higher-field region forms at the bottleneck point, or furrow, between the two newly forming cells, as shown in figure 2b . The nonuniform electric field generates a so-called dielectrophoretic force that draws polarizable molecules and structures in the direction of the higher-field region. The researchers calculate that the force, which can be as large as 60 pN, is enough to cause the organelles to pile up at the furrow within a few minutes.
Just how that pileup destroys the cell is still largely a matter of speculation, but Palti and his colleagues have a few ideas. "The organelles are attached to a cytoskeleton," Palti says. "They're not just floating around in the cytoplasm," so maybe the dielectrophoretic force rips them from that connective structure and kills the cell. Also, the pinchingoff mechanism, by which the furrow closes and one cell becomes two, is a sensitive process that could be disrupted by the presence of molecules and organelles that are supposed to be elsewhere in the cell.
Palti's 100-kHz fields are not the only form of electrical stimulation that can hinder cell division. Luca Cucullo, Damir Janigro, and their colleagues at the Cleveland Clinic have found that low-intensity alternating current with a much lower frequency-about 50 Hzcan keep some types of cells from dividing. 3 They don't yet know exactly how the process works, but their experiments suggest that the mechanism involves a particular protein that forms pores in the cell membrane to transport potassium ions into the cell. Cells whose division was halted by electric current contained more than the usual amount of the protein. And when the stimulated cells were exposed to cesium or barium, which block the potassiumtransport pores, they divided at the same rate as unstimulated cells.
Clinical trial
Palti and colleagues had extensively studied the effects of the electric fields on tumor cells in vitro and in laboratory mice and rats when in 2003 they began their first clinical trial on human patients. They used their electric fields to treat glioblastoma multiforme (GBM), a type of brain tumor with a very low survival rate. When the tumor is treated by surgery, radiation, or chemotherapy, it nearly always progresses, or starts to grow again. The tumor usually kills the patient, often by the buildup of intracranial pressure that results from the tumor's sheer size.
The researchers recruited 10 patients for their trial. All had recurrent GBM, meaning that their tumors had been treated by other methods and had begun to grow again. The patients were fitted with electrodes, as shown in figure 3 , that applied a 200-kHz electric field to their brains. At one-second intervals, the field orientation switched between front to back and side to side, so that the field would have the greatest effect on tumor cells dividing in all directions. Patients wore the electrodes 18 hours per day for up to 18 months.
Healthy cells in an adult brain don't divide, so there was little danger that the electric field would damage the normal tissue surrounding the tumor. In fact, because of the way applied fields are distributed in the body, the researchers are confident that when they apply their treatment to tumors in other parts of the body, the fields will do little damage to the bone marrow or the digestive tract. The field strength that could be used was limited not by toxicity to healthy tissues but by thermal effects in the skin: The field intensity was automatically lowered if the skin was heated enough to be in danger of thermal damage. The patients didn't lose their hair, but they had to keep their heads shaved in order for the electrodes to make good contact.
Because their small trial had no control group, the researchers compared their device's performance with historical data from other studies of GBM patients. Palti's trial found a median time to progression of 26 weeks and a median survival time of 62 weeks, whereas studies of recurrent GBM treated by other means found a time to progression of about 10 weeks and a survival time of about 30 weeks. Two years after their treatment began, 3 of the 10 patients in Palti's trial were still alive, and two were progression free.
To better evaluate their treatment's effectiveness, Palti and colleagues are currently working on a controlled study in which patients are randomly assigned to receive either the electricfield treatment or a chemotherapy regimen. They are also looking into combining the electric-field treatment with low-dose chemotherapy. Johanna Miller Figure 3 . A brain-tumor patient receiving electric-field treatment. Electrodes affixed to the scalp, fed by the 3-kg battery-powered device in the gray and black bag, apply alternating electric fields to the tumor site. Since the device is portable, patients can go about their normal activities while being treated for 18 hours a day.
